Mexico: The War for the Allopathic Medicament Market in Mexico

Last Updated: 20 February 2003
Article by Oscar González-Vazquez

Most Read Contributor in Mexico, November 2018

Who could have imagined the current situation of the allopathic medicament market in Mexico 4 years ago?

Approximately four years ago, a tripartite advertising war in the massive communication media took place between laboratories manufacturing allopathic medicaments, that is, innovative medicaments or patent-protected medicaments, laboratories manufacturing interchangeable generic medicaments (GI’s by their initials in Spanish language), and laboratories manufacturing generic or "similar" (look-alikes) medicaments. In this war, each part enhanced the advantages of their products, emphasizing particularly in their respective costs.

The struggle still persists, and this conflict is being taken to other spheres besides the commercial ambit. For instance, the company "Farmacia de Similares" (Similars Pharmacy), which sells medicaments from the "similar" category, has publicly denounced that the Federal Consumers Representative (PROFECO), the Mexican Institute of Industrial Property (MIIP) and the Ministry of Health (MOH) are acting against it, because on the one hand, the first two organizations have emitted resolutions ordering "Farmacia de Similares" to remove its advertising campaign slogan "the same but cheaper", because it is considered as unlawful competition. On the other hand, "Farmacia de Similares" argues that the MOH is pretending to eliminate it from the market by modifying the standards for governmental acquisitions, because now, the MOH will demand only patent-protected medicaments or interchangeable generic medicaments (GI’s), which satisfactorily approve with the standards of bioequivalency tests.

As it can be seen, this dispute between laboratories is turning more intense as interesting each time, if we take into account that the allopathic medicament market in México is within the first ten in the world, and that it is number one in Latin America. Hence, we do not have to say that too many economical interests are at stake.

Many may wonder why does this conflict exists; well, the answer goes as follows:

Before implementing the interchangeable generic medicament program (commercially designated as GI’s) in 1998, there were only innovative or patent-protected medicaments and generic or similar medicaments in the market.

In 1991, the World Health Organization (WHO) had recommended the Mexican Government implementing a program for interchangeable generic medicaments. It was until 1998, that the MOH reformed the General Health Law (GHL), establishing the basis for the Interchangeable Generic Medicament Program. Since then, all official agreements by which a pharmaceutical product is rendered susceptible to be incorporated to the Interchangeable Generic Medicaments Catalogue, are published in the Official Diary of the Federation.

An interchangeable generic (GI) medicament is a medicament containing the same active ingredient as well as the same pharmaceutical dosage form of the corresponding innovative or patent-protected medicament, having then equal effectiveness and concentration. It also utilizes the same via of administration. Besides, an interchangeable generic medicament is required to approve the standards of the interchangeability tests, which certify it as a pharmaceutically equivalent medicament to the innovative medicament, this GI then showing to be as effective and safe as the innovative medicament, but at a lower market price. One of the main features of a GI is that it must be released in the market once the patent of the innovative medicament is no longer in force.

Now then, the generic or similar medicaments have been in the pharmaceutics market since long ago, conforming, above all, the source of the Basic Chart of consumable resources for the Health Sector. One of the possible reasons this happened was that, well before the enactment of the Industrial Property Law (IPL) of 1991 which was amended in 1994, many inventions were considered as non-patentable, including all types of pharmaceutical and biotechnological inventions. Hence, there was no protection of property rights for innovative medicaments, and therefore, the innovative medicaments market was very reduced.

Thus, from the date said IPL of 1991 was enacted, a broad protection of property rights was totally available for said pharmaceutical and biotechnological inventions. Mexico then became one of the most promising markets in the international sphere for foreign research and development foreign laboratories, as this amendment of the Law allowed innovative medicaments to increase their presence in the national market.

On the other hand, at the same time the GI’s appeared in the market, "Farmacia de Similares" had an accelerated growth in most of the national territory, accompanied by a powerful advertising campaign in the massive media, which slogan wielded that "similars" are equal to the innovative medicaments, but cheaper, although their purity and effectiveness had been questioned by the Health Authorities.

As a response to the "similars" advertising campaign, the manufacturers of GI’s, and of innovative medicaments, initiated, independently, their own advertising campaign in order to work against the "similars" campaign, by making tacit comparisons of the therapeutic effect of said innovative and interchangeable medicaments compared with that of the similars.

Another factor that has played a fundamental role in this conflict is the Sanitary Regulation, which affects at least two actors of this conflict, since, on the one hand, the MOH grants sanitary registrations (marketing authorizations) to all medicaments, without considering if the innovative medicament is still protected under a valid patent, reason for which the interests of said innovative medicaments are affected. On the other hand, however, nor the GHL neither its Regulation consider a continuous renovation schedule for sanitary registrations issued a long time ago, which greatly affects the GI’s.

Delving a little more into the first mentioned aspect, we now will refer to the complain the foreign pharmaceutical laboratories have presented, in the sense that the Health Authorities should not grant the sanitary registration to a generic interchangeable medicament or to a similar medicament until the patent protecting the innovative medicament is due, so the IPL as the international treaties of which Mexico is a party, are respected. Nevertheless, the health authorities have not listened to said petition, arguing that patents are not in their area of competency.

Regarding the second above aspect, it is important to mention that if there is a third laboratory interested in releasing a generic medicament in the market, it can meet with the MOH purity and effectiveness requirements for a generic medicament only by showing any document that certifies said conditions. Said documents can be copies of the studies done originally by the research laboratory for the innovative medicament, which can be obtained via Internet from the Food and Drug Administration (FDA) in the USA.

But, what has caused this war between laboratories?

The advertising war initiated approximately 4 years ago, has originated a great amount of confusion in the public, mainly in the people with less economical resources, because they are filled with ads referring to the advantages of each of the medicament categories. These ads also enhance the differences in prices of one with respect to the others, a fact which is difficult to understand if people do not have the elements at hand in order to make a real comparison.

On the other hand, we can mention that there also is a great deal of ignorance between the medical sector, since there is an elevated number of medics who are not aware of the pharmacological and therapeutic difference between each one of the aforementioned categories of medicaments, independently of their price, fact which aggravates the situation if we consider that the medic is the ideal person to guide their patients and prescribe them the medicament which is the safest and the most effective, so the disorder lasts the least.

Viewing the problem through this optic, I consider that a great sector of the population requiring of medicaments, buy these only because of their low price, without considering the other facts.

Together with the problems mentioned above, it is important to mention that in Mexico, until now, a policy for protection against health risks in matter of medicaments has not been really instrumented, even though the Federal Commission for Protection against Health Risks (COFEPRIS) has been created. The above is completely evident, as there is not any health control or vigilance in stores or drugstores that sell medicaments, since a prescription is not required to buy them even though the label of the medicament quotes according to the law: "prescription is required for selling or supplying of this medicament", these medicaments becoming therefore, "free-access" medicaments. This fact contributes to self-medication in a considerable manner.

With this panorama, it is necessary to attack the problem from the root by giving in-depth solutions and not simply temporary or superficial remedies which partially alleviate the conflict. For that purpose, I consider that it is essential to define a medicament policy suitable to the globalization times we are living, promoting more legal safety and equity in the pharmaceutical sector.

To achieve the aforementioned, it is fundamental to amend the GHL and its Regulations, in order that the granting of the required sanitary registrations is subject to the dispositions of the IPL and to the International Treaties of which Mexico is a party, besides meeting with the requirements indicated in the applicable norm.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
 
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions